Drug Trial Radar · NCT05470608
Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain
Last checked: Nov 19, 2026Latest source record: Aug 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
132
Planned (sponsor's estimate)
Start
Jun 13, 2022
Primary completion
Jan 2024
Study completion Jan 2024
Sponsor
- Lead sponsor
- Saol Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, single ascending dose escalation study to assess the safety and efficacy of single treatment exposure of an injectable formulation of SL-1002 for the treatment of knee pain associated with osteoarthritis. Phase A of the study will enroll 3 cohorts of 8 patients per cohort, for a total of 24 patients. Patients will be randomized to receive either SL-1002 or placebo in a 3:1 ratio within each given cohort. Phase B of the study will enroll a minimum of 92 up to a maximum of 108 patients. Patients will be randomized to receive either SL-1002 or placebo in a 3:1 ratio at the recommended dose determined from Phase A. The study period will be up to 168 days inclusive of a screening period of up to 28 days.
Conditions
- Osteoarthritis, Knee Pain
Interventions
SL-1002Drug
SL-1002 injectable solution
PlaceboDrug
Matching placebo injectable solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of treatment emergent adverse events (TEAEs) overallTime frame: Time of study drug administration to end of study visit (day 168)
- Improvement of knee painTime frame: Change from baseline to Month 3 in 11 point NRS score
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Denver Spine & Pain Institute
Greenwood Village, Colorado
International Spine, Pain & Performance Center
Washington D.C., District of Columbia
Prime Medical Research
Coral Gables, Florida
Conquest Research
Winter Park, Florida
Northwestern University
Chicago, Illinois
Mayo Clinic
Rochester, Minnesota
Cooper Neurological Institute
Camden, New Jersey
Center for Clinical Research
Winston-Salem, North Carolina
Pacific Sports and Spine
Eugene, Oregon
University Orthopedics Center
Altoona, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Institute of Precision Pain Medicine
Corpus Christi, Texas
Precision Spine Care
Tyler, Texas
University of Utah School of Medicine
Salt Lake City, Utah
Virginia iSpine Physicians
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.